<br />
RHEUMATOLOGY<br />
ACR/ARHP supplement • emjreviews.com<br />
INSIDE<br />
American College of Rheumatology/<br />
Association of Rheumatology Health<br />
Professionals (ACR/ARHP)<br />
2015 Meeting Highlights:<br />
New Data on Canakinumab<br />
AMERICAN COLLEGE OF RHEUMATOLOGY/<br />
ASSOCIATION OF RHEUMATOLOGY HEALTH<br />
PROFESSIONALS (ACR/ARHP) 2015 MEETING<br />
HIGHLIGHTS: NEW DATA ON CANAKINUMAB<br />
*Caroline Charles<br />
Scilink Medical Writing, Biarritz, France<br />
*Correspondence to scilink.mw@gmail.com<br />
Disclosure: The author has declared no conflicts of interest.<br />
Support: The publication of this article was funded by Novartis. The views and opinions expressed are those<br />
of the authors and not necessarily of Novartis.<br />
Received: 25.11.15 Accepted: 19.04.16<br />
Citation: EMJ Rheumatol. 2016;3(Suppl 5):2–10.<br /> <a title="EMJ Rheumatol. 2016 Suppl 5 page 1" href="http://viewer.zmags.com/publication/0656c029?page=1"> RHEUMATOLOGY ACR/ARHP supplement • emjreviews.com</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 2" href="http://viewer.zmags.com/publication/0656c029?page=2"> AMERICAN COLLEGE OF RHEUMATOLOGY/ ASSOCIATION O</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 3" href="http://viewer.zmags.com/publication/0656c029?page=3"> following the results of a double-blind, placebo-</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 4" href="http://viewer.zmags.com/publication/0656c029?page=4"> vaccines. Post-vaccination antibody titres we</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 5" href="http://viewer.zmags.com/publication/0656c029?page=5"> Efficacy and Safety of Canakinumab in Children wi</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 6" href="http://viewer.zmags.com/publication/0656c029?page=6"> events were then adjudicated, blinded to treatmen</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 7" href="http://viewer.zmags.com/publication/0656c029?page=7"> NEW DATA PRESENTED AT ACR/ARHP 2015 ON CANAKINUMA</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 8" href="http://viewer.zmags.com/publication/0656c029?page=8"> with the TA (362.7/100 pyr) group. The exposure- </a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 9" href="http://viewer.zmags.com/publication/0656c029?page=9"> 10. Neven B et al. Cryopyrinopathies: Update</a>
<a title="EMJ Rheumatol. 2016 Suppl 5 page 10" href="http://viewer.zmags.com/publication/0656c029?page=10"> 44. Sunkureddi P et al. Efficacy and safety an</a>